Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 1999

View Archived Issues

Gene that causes familial British dementia discovered

Onyvax and Erasmus University reach prostate cancer agreement

Cambridge Combinatorial to provide chemistry services to Pfizer

Pharming begins phase I development of human lactoferrin

FDA grants orphan drug designation for Ceresine in traumatic brain injury

CollaGenex signs marketing agreement for Periostat in Canada

Cerus initiates phase I allogeneic bone marrow transplant study

Amylin initiates phase II study of AC-2993 in type II diabetes

Novo Nordisk seeks approval for liquid GH in the U.S.

GW-420867X is a promising component of anti-HIV combination therapy

DAPD: another promising agent for combination therapy of HIV/AIDS

Howard Hughes researchers uncover mechanism of interferon resistance in HCV

Neuroprotectants in early development at Pharmacia & Upjohn

Thienopyrimidine inhibitors of PDE5 described by Merck KGaA

P&U studies compounds that intervene in the kynurenine metabolic pathway

Epimmune-Cytel merger complete; new company up and running

Astra (AstraZeneca) presents new agents for GI inflammatory disorders

Alsterpaullone is a potent CDK1/cyclin B inhibitor and antitumor agent

New compounds from Senju under evaluation for complications of diabetes

Antifungal triazoles patented by SS Pharm.

Fujisawa prepares new cephem antibiotics

Russian scientists test GVS-111 in preclinical assays

Renal allograft survival is prolonged by treatment with anti-CD4-idarubicin immunoconjugate

NCC-1048 is a novel neuronal calcium channel blocker with potential in cerebral ischemia

Stable HLE inhibitors with in vivo activity in lung hemorrhage model identified at Chinoin

Novel noncompetitive AMPA antagonist presented at European Congress of Pharmacology

Kissei seeks approval of amprenavir in Japan

Noncompetitive AMPA receptor antagonist emerges as development candidate for stroke, epilepsy, etc.

Second-generation PDE4 inhibitors highlighted at World Congress on Inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...